



CHAIR

Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

COCHAIRS

Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX
Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY
Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

* - ICML Representative

[R] – recorded presentation with remote Q&A/discussion

WEDNESDAY, JUNE 19

Registration

3:30-8:30 P.M. | Liberty Foyer

Welcome and Opening Keynote Lecture

6-7 P.M. | Liberty B

6-6:10	Welcome and Introduction of Keynote Speaker Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
6:10-7	Metabolic regulation of lymphoma development Tak W. Mak. UHN Princess Margaret Cancer Centre. Toronto. ON. Canada

Plenary Session 1: Signaling / Immune Synapse

7-8:45 P.M. | Liberty B

Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

7-7:05	Introduction
	Francesco Bertoni
7:05-7:25	Oncogenic signaling in T-cell and B-cell lymphoma
	Jürgen Ruland, Technical University of Munich, Munich, Germany
7:25-7:30	Discussion / Q&A
7:30-7:50	Lymphoma immune microenvironment shaping receptivity to various immunological therapeutic strategies
	Roberta Zappasodi, Weill Cornell Medicine, New York, NY
7:50-7:55	Discussion / Q&A



7:55-8:15	Resistance mechanisms to BTK inhibitors
	Francesco Bertoni
8:15-8:20	Discussion / Q&A
8:20-8:45	Panel Discussion / Q&A

Opening Reception

8:45-10:15 P.M. | Liberty A

THURSDAY, JUNE 20

Continental Breakfast

7:30-8:30 A.M. | Liberty A

Spotlight on Proffered Papers Session

8:30-9:55 A.M. | Liberty B

Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30-8:35	Introduction Michael R. Green
8:35-8:46	EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions Yusuke Isshiki, Weill Cornell Medicine, New York, NY
8:46-8:57	Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients Nahuel Zamponi, Weill Cornell Medicine, New York, NY
8:57-9:08	Immunosurveillance of precancerous germinal center B cells Dinis Pedro Parente Calado, The Francis Crick Institute, London, United Kingdom
9:08-9:19	Characterization of an essential <i>MYC</i> enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma Aishwarya Gurumurthy, University of Michigan, Ann Arbor, MI
9:19-9:30	Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas Wen-Hsuan Wendy Lin, Columbia University Irving Medical Center, New York, NY





9:30-9:41	Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy Xubin Li, The University of Texas MD Anderson Cancer Center, Houston, TX
9:41-9:52	SETD1B mutations confer apoptosis resistance and BCL2 independence in B-cell Lymphoma Ana Portelinha, Memorial Sloan Kettering Cancer Center, New York, NY

Break

9:55-10:15 A.M. | Liberty Foyer

Plenary Session 2: Germinal Center Biology and its Role in Lymphomagenesis

10:15 A.M.-12 P.M. | Liberty B

Session Chair: Coraline Mlynarczyk, Weill Cornell Medicine, New York, NY

10:15-10:20	Introduction Coraline Mlynarczyk
10:20-10:40	Regulating programmed DNA lesions in B cells Jayanta Chaudhuri, Memorial Sloan Kettering Cancer Center, New York, NY
10:40-10:45	Discussion / Q&A
10:45-11:05	Competition in the germinal center Coraline Mlynarczyk
11:05-11:10	Discussion / Q&A
11:10-11:30	T-cell dependent acquisition of stem-like plasticity in Germinal Center B cells Effie Apostolou, Weill Cornell Medicine, New York, NY
11:30-11:35	Discussion / Q&A
11:35-12	Panel Discussion / Q&A

Free time / Lunch on own

12-1:30 P.M.





Plenary Session 3: Premalignant Processes in Lymphomagenesis

1:30-3:15 P.M. | Liberty B

Session Chair: Jagan Muppidi, National Cancer Institute, Bethesda, MD

1:30-1:35	Introduction Jagan Muppidi
1:35-1:55	Lymphoid clonal hematopoiesis and its relationship to monoclonal B-cell lymphocytosis Aswin Sekar, Dana-Farber Cancer Institute, Boston, MA
1:55-2	Discussion / Q&A
2-2:20	Control of nutrient driven proliferation in mucosal germinal centers by the tumor suppressor <i>GNA13</i> Jagan Muppidi
2:20-2:25	Discussion / Q&A
2:25-2:45	Expanded T cell clones with lymphoma driver somatic mutations in refractory celiac disease
2:45-2:50	Mandeep Singh, Garvin Institute of Medical Research, Sydney, Australia Discussion / Q&A
2:50-3:15	Panel Discussion / Q&A

Break

3:15-3:35 P.M. | Liberty Foyer

Plenary Session 4: Lymphoma Clonal Precursors and Transformation

3:35-5:20 P.M. | Liberty B

Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY

3:35-3:40	Introduction Ari M. Melnick
3:40-4	The elusive lymphoma clonal precursor cell Ari M. Melnick
4-4:05	Discussion / Q&A
4:05-4:25	Deciphering and intercepting follicular lymphoma clonal precursor cells Sandrine Roulland, Aix-Marseille University, Marseille, France
4:25-4:30	Discussion / Q&A





4:30-4:50	Transformation to aggressive lymphoma: Molecular basis and detection
	Erin M. Parry, Dana-Farber Cancer Institute, Boston, MA
4:50-4:55	Discussion / Q&A
4:55-5:20	Panel Discussion / Q&A

Poster Session / Reception

5:30-7:30 P.M. | Liberty A

Evening off / Dinner on own

7:30 P.M.-

FRIDAY, JUNE 21

Continental Breakfast

7:30-8:30 A.M. | Liberty A

Plenary Session 5: Lymphoma Etiology and Outcomes- The Role of Age and Ethnicity

8:30-10:15 A.M. | Liberty B

Session Chair: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30-8:35	Introduction Christopher R. Flowers
8:35-8:55	The etiology of pediatric lymphoma Lisa G. Roth, Weill Cornell Medicine, New York, NY
8:55-9	Discussion / Q&A
9-9:20	An aged/autoimmune origin to B cell lymphomas Leandro Venturutti, BC Cancer, Vancouver, BC, Canada
9:20-9:25	Discussion / Q&A
9:25-9:45	Disparities in lymphoma Christopher R. Flowers
9:45-9:50	Discussion / Q&A
9:50-10:15	Panel Discussion / Q&A

Break

10:15-10:35 A.M. | Liberty Foyer





Plenary Session 6: Lymphoma Epigenetics

10:35 A.M.-12:15 P.M. | Liberty B

Session Chair: Laura Pasqualucci, Columbia University, Institute of Cancer Genetics, New York, NY

10:35-10:40	Introduction Laura Pasqualucci
10:40-11	Epigenetic therapies in T-cell lymphoma Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY
11-11:05	Discussion / Q&A
11-11:20	Disentangling truncating and missense CREBBP mutations in B cell lymphoma Laura Pasqualucci
11:20-11:25	Discussion / Q&A
11:25-11:45	Perturbation of cell state transitions by epigenetic mutations Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
11:45-11:50	Discussion / Q&A
11:50-12:15	Panel Discussion / Q&A

Free time / Lunch on own

12:15-1:45 P.M.

Plenary Session 7: Lymphoma Microenvironment / Tumor Immunology of Lymphoma

1:45-3:30 P.M. | Liberty B

Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

1:45-1:50	Introduction
	Margaret A. Shipp
1:50-2:10	Bispecific antibodies in lymphoma therapy
	Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark
2:10-2:15	Discussion / Q&A
2:15-2:35	The lymphoma microenvironment
	Margaret A. Shipp
2:35-2:40	Discussion / Q&A



2:40-3	Multi-omic profiling of the follicular lymphoma tumor microenvironment
	Andrea J. Radtke, National Institute of Allergy and Infectious Disease, Bethesda, MD
3-3:05	Discussion / Q&A
3:05-3:30	Panel Discussion / Q&A

Break

3:30-3:50 P.M. | Liberty Foyer

Plenary Session 8: New Approaches in CAR T-cell Therapy

3:50-5:30 P.M. | Liberty B

Session Chair: Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

3:50-3:55	Introduction Michel Sadelain
3:55-4:15	Logic gating of CAR T cells: OR and IF-BETTER Michel Sadelain
4:15-4:20	Discussion / Q&A
4:20-4:40	Clonotype-specific CAR T Marco Ruella, University of Pennsylvania, Philadelphia, PA
4:40-4:45	Discussion / Q&A
4:45-5:05	How to make CART cells work in spite of lymphoma immune evasion mechanisms Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, NY
5:05-5:10	Discussion / Q&A
5:10-5:30	Panel Discussion / Q&A

Evening off / Dinner on own

5:30 P.M. -

SATURDAY, JUNE 22

Continental Breakfast

7-8 A.M. | Liberty A





Keynote Lecture

8-9 A.M. | Liberty B

8-8:05 Introduction of Keynote Spea	aker
-------------------------------------	------

Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

8:05-9 Toward the noninvasive characterization of lymphomas & their microenvironments

Ash A. Alizadeh, Stanford University, Stanford, CA

Plenary Session 9: Chemo-free Approaches to Lymphoma

9-10:45 A.M. | Liberty B

Session Chair: Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, TX

9:00-9:05	Introduction Jason Westin
9:05-9:25	We will still use RCHOP in 2034? Jason Westin
9:25-9:30	Discussion / Q&A
9:30-9:50	Targeted treatment of DLBCL Christopher J. Melani, National Cancer Institute, Bethesda, MD
9:50-9:55	Discussion / Q&A
9:55-10:15	Rewiring cancer drivers to activate apoptosis Gerald R. Crabtree, Stanford University, Stanford, CA
10:15-10:20	Discussion / Q&A
10:20-10:45	Panel Discussion / Q&A

Break

10:45-11 A.M. | Liberty Foyer

Plenary Session 10: Bringing Genomics from Bench to Bedside

11 A.M.-12:45 P.M. | Liberty B

Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

11-11:05 Introduction

Michael R. Green

11:05-11:25 Precision therapy based on somatic mutation profiles

H. Christian Reinhardt, Essen University Hospital, Essen, Germany

Advances in Malignant Lymphoma:

Program as of 7/2/2024 9:08 PM

Maximizing the Basic-Translational Interface for Clinical Application In cooperation with the International Conference on Malignant Lymphoma (ICML)

June 19-22, 2024

Page 8 of 9

In association with Blood Cancer Discovery

Sheraton Philadelphia Downtown | Philadelphia, PA





11:25-11:30	Discussion / Q&A
11:30-11:50	T-cell lymphoma molecular classifications that inform therapy Catalina Amador, University of Miami Miller School of Medicine, Miami, FL
11:50-11:55	Discussion / Q&A
11:55-12:15	[R] - Genetic subtype-guided immunochemotherapy in DLBCL Wei-Li Zhao, Ruijin Hospital, Shanghai, China
12:15-12:20	Discussion / Q&A
12:20-12:45	Panel Discussion / Q&A

Departure

12:45 P.M.